OnCo · weekly issue

OnCo weekly, 2026-09-09

9 changelog entries, 1 regulatory events, 1 upcoming dates, 40 publications, 3 corrections. Generated from the corpus; every item links to its page and, through it, to the primary source. Not medical advice.

Release 0.4.0 (2026-09-08)

From CHANGELOG.md.

Added: Animated wireframe schematics for all 18 fronts (front pages, Fronts index, home) and for all 19 glossary term categories (/terms/ and every term page).
Added: Molecule thumbnails wherever a product is mentioned: cards in pipelines, connected lists, and product tabs; hover popover with the rotating molecule on inline drug chips.
Added: Self-hosted organisation logos under public/logos/ (Wikimedia Commons via Wikidata with domain verification, favicon fallback) for companies, institutions, and collections.
Added: person kind (clinicians and scientists: role, specialisms, profiles, papers) with a People index and a People tab on institution pages.
Added: Site favicon and Apple touch icon; GitHub link in the header.
Added: Public-readiness: CI workflow, issue and pull-request templates, Code of Conduct, security policy, consolidated contributing guide.
Changed: Graph explorer rebuilt as a clean radial view (fronts inner ring, cancers outer ring) with a focus mode that groups neighbours by kind; no physics.
Changed: Header language and theme controls are single-line and compact.
Changed: Footer and About page carry the work-in-progress disclaimer: verify every fact at its primary source; not medical advice.

Regulatory events, past 7 days

Dated filings, approvals, letters and label changes recorded on product pages.

2026-09-04 · Camizestrant · approval (US): Accelerated approval (Etcamah) source

Next 30 days

Decisions, advisory committees, expected readouts and congresses from the readout calendar. Expected dates are editorial estimates.

2026-09-23 · FDA advisory committee: Galleri multi-cancer early detection test (PMA) (confirmed) · Galleri, GRAIL, Multi-cancer early detection (MCED), NHS-Galleri, PATHFINDER 2 · source

What the journals and regulators published, past 14 days

From the research pulse; every item links to the source.

2026-09-08 · Inhibrx claims first win for the long-sought OX40 target: Responses in head and neck cancer, strongest in HPV-positive tumours, after 15 years of failed OX40 programmes at big pharma. (Head and neck squamous cell carcinoma, Immune checkpoint inhibitors)
2026-09-08 · A breakthrough pancreatic cancer drug won approval. Patients still struggle to access it: Insurance barriers after the daraxonrasib approval. (Daraxonrasib, Pancreatic ductal adenocarcinoma)
2026-09-08 · Metabolic syndrome commonly develops in men on ADT plus ARPI: About 40% within a year, per the reported analysis. (Androgen deprivation & AR pathway inhibitors, Prostate cancer, Cardio-oncology)
2026-09-08 · Azacitidine/venetoclax boosts event-free survival in induction-eligible AML: Coverage of the NEJM head-to-head with intensive chemotherapy. (Azacitidine, Venetoclax, Acute myeloid leukaemia)
2026-09-08 · Alcohol-attributable cancer mortality has doubled in the US since 1990: Prevention story with policy implications. (Chemoprevention & risk-reducing surgery)
2026-09-08 · DeLLphi-305: durvalumab + tarlatamab meets OS in first-line maintenance ES-SCLC: 563 patients; first phase 3 T-cell engager OS win in first-line maintenance small-cell lung cancer; numbers pending a congress. (Tarlatamab, Durvalumab, DeLLphi-305, Small-cell lung cancer)
2026-09-08 · Arlocabtagene autoleucel meets primary endpoint in the QUINTESSENTIAL myeloma trial: The GPRC5D CAR-T advances toward filing. (GPRC5D, CAR-T cell therapy, Multiple myeloma)
2026-09-07 · KEYLYNK-001: pembrolizumab ± olaparib maintenance in BRCA-wild-type ovarian cancer: Vergote et al., 7 September: the immunotherapy–PARP maintenance question in first line. (Pembrolizumab, Olaparib, Ovarian cancer, PARP inhibitors)
2026-09-07 · Lessons from one of the first randomised trials of AI in medicine: Lång, 7 September: what the MASAI mammography-AI trial taught about running AI trials. (AI in radiology, Mammography & tomosynthesis)
2026-09-07 · Oncology dealmaking is becoming more surgical: Buyers target specific modalities and assets rather than platforms. (Antibody-drug conjugate (ADC), Radioligand therapy (beta emitters))
2026-09-05 · Six first-in-class approvals in August, including Etcamah: Camizestrant counted among August's first-in-class approvals. (Camizestrant)
2026-09-04 · Accelerated approval: camizestrant + CDK4/6 inhibitor for ESR1-mutated HR+/HER2- breast cancer: Etcamah approved 4 September after a 6-3 negative advisory vote, on SERENA-6 ctDNA-guided switching data. (Camizestrant, SERENA-6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer)
2026-09-04 · Etcamah grabs FDA approval for advanced breast cancer with ESR1 mutations: Camizestrant plus a CDK4/6 inhibitor, accelerated approval. (Camizestrant, HR-positive / HER2-negative breast cancer)
2026-09-04 · Targeting fibroblast activation suppresses chemotherapy-induced pro-invasive remodelling: Stroma as a therapeutic target after chemotherapy. (FAP, Epithelial–mesenchymal transition & drug efflux)
2026-09-03 · Daraxonrasib for previously treated RAS-mutant NSCLC: Arbour et al., 3 September: the pan-RAS inhibitor shows activity beyond pancreatic cancer. (Daraxonrasib, KRAS, Non-small-cell lung cancer)
2026-09-03 · Azacitidine-venetoclax or induction chemotherapy for AML: Fathi et al., 3 September: the chemotherapy-free doublet compared head to head with 7+3 in fit patients, with an accompanying editorial. (Azacitidine, Venetoclax, Acute myeloid leukaemia, VIALE-A)
2026-09-03 · Molecularly guided therapy vs chemotherapy in cancer of unknown primary (CUPISCO): Krämer et al., 3 September: genomics-directed treatment tested in a randomised trial. (Comprehensive genomic profiling, Companion diagnostics)
2026-09-03 · Pan-RAS inhibitor shows activity in advanced lung cancer: News digest, 3 September, on the NEJM daraxonrasib NSCLC data. (Daraxonrasib, KRAS, Non-small-cell lung cancer)
2026-09-03 · Daraxonrasib exhibits 'encouraging signal' in RAS-mutant metastatic lung cancer: The pancreatic drug's NEJM lung data. (Daraxonrasib, Non-small-cell lung cancer)
2026-09-03 · DLL3 expression predicts response and long-term outcome in SCLC: Biomarker work relevant to tarlatamab and DLL3 engagers. (DLL3, Tarlatamab, Small-cell lung cancer)
2026-09-01 · HARMONi: ivonescimab plus chemotherapy after EGFR-TKI failure: Le et al.: the global phase 3 of the PD-1×VEGF bispecific in EGFR-mutant NSCLC, PFS positive with OS not statistically significant. (Ivonescimab, Non-small-cell lung cancer, EGFR, PD-1)
2026-09-01 · AI-based TIL quantification in TNBC: independent validation: Dixon-Douglas et al. and a companion APHINITY analysis compare manual, digital, and AI TIL scoring. (Tumour-infiltrating lymphocytes (TILs), Digital pathology & AI, Triple-negative breast cancer (TNBC), APHINITY)
2026-09-01 · GETUG-AFU 18: dose-escalated radiotherapy with long-term ADT in high-risk prostate cancer: Hennequin et al.: higher dose improves progression-free survival. (IMRT / IGRT (modern external beam), Androgen deprivation & AR pathway inhibitors, Prostate cancer)
2026-09-01 · SHR-A2102, a Nectin-4 ADC, in pretreated solid tumours (phase 1): Zhong et al.: a Chinese Nectin-4 ADC beyond urothelial cancer. (Nectin-4, Antibody-drug conjugate (ADC), Enfortumab vedotin)
2026-09-01 · Ifebemtinib plus garsorasib in KRAS G12C colorectal cancer (phase 1b/2): Song et al.: a FAK inhibitor plus a G12C inhibitor, another route around the CRC feedback problem. (KRAS, Colorectal cancer, KRAS & RAS inhibitors)
2026-09-01 · NSABP B-59/GeparDouze: atezolizumab in early TNBC: Loibl et al., 1 September: the randomised phase 3 of PD-L1 blockade in the curative setting. (Atezolizumab, Triple-negative breast cancer (TNBC), Immune checkpoint inhibitors, KEYNOTE-522)
2026-09-01 · Tumour-secreted ADAMTSL4 activates latent TGFβ1 to drive cancer cachexia: Machado et al., 1 September: a new mechanism behind the wasting that kills many patients. (Supportive Care & Survivorship)
2026-09-01 · Long-read haplotype phasing as a missing layer of precision oncology: Vo et al., 1 September: allelic configuration changes how some variants should be interpreted. (Whole-exome & whole-genome sequencing, Comprehensive genomic profiling)
2026-09-01 · ASCENT-04 exploratory analysis: sacituzumab govitecan + pembrolizumab improves PFS2: Benefit of the ADC-immunotherapy first line carries into the next line in PD-L1+ TNBC. (Sacituzumab govitecan, Pembrolizumab, ASCENT-04 / KEYNOTE-D19, Triple-negative breast cancer (TNBC))
2026-09-01 · Geriatric oncology at ASCO 2026: the next challenge is implementation: Trials show assessment-guided care cuts toxicity; the field now has to deliver it routinely. (Geriatric assessment)
2026-09-01 · MD Anderson president announces retirement: Peter Pisters retiring; Jeffrey Lee named interim president. (MD Anderson Cancer Center)
2026-09-01 · Long-course chemoradiotherapy shows early organ-preservation advantage in rectal cancer: Extended treatment improves mesorectal-excision-free survival versus short course. (Colorectal cancer, IMRT / IGRT (modern external beam))
2026-09-01 · Medicus Pharma secures worldwide rights to Pfizer's discontinued CD228 ADC: A deal valued over $1 billion for a shelved programme, a sign of ADC demand. (Antibody-drug conjugate (ADC), Pfizer (incl. Seagen))
2026-08-31 · Radiopharmaceutical experts push the bounds of dosing: Louise Emmett and others argue industry is too cautious on dosing frequency; kidney, liver, and marrow toxicity have already ended at least one company. (Radioligand therapy (beta emitters), Targeted alpha therapy, Lutetium-177 vipivotide tetraxetan)
2026-08-31 · After a rough stretch, mRNA gets a boost: Politics and science collide as mRNA cancer vaccines regain momentum. (Personalised neoantigen (mRNA) vaccines, Moderna, BioNTech)
2026-08-31 · Pipeline Watch, August 2026: dealmaking accelerates: Licensing, a pivotal lung readout, and Treg-directed conjugates. (Antibody-drug conjugate (ADC), Bispecific ADC)
2026-08-31 · After CAR-T relapse in mantle cell lymphoma, a CD79b ADC produces durable remission: Sequencing modalities in lymphoma. (Antibody-drug conjugate (ADC), CAR-T cell therapy, Diffuse large B-cell lymphoma)
2026-08-29 · LLM-assisted evidence audit of late-stage cancer incidence as a screening trial endpoint: Directly relevant to the NHS-Galleri result and the FDA advisory committee. (Multi-cancer early detection (MCED), NHS-Galleri, Galleri, Stage shift)
2026-08-28 · AEGEAN update: perioperative durvalumab in resectable NSCLC: Heymach et al., 28 August: longer follow-up of the perioperative PD-L1 regimen. (Durvalumab, Non-small-cell lung cancer, Immune checkpoint inhibitors)
2026-08-27 · Lymphodepletion mitigates anti-CAR immunity in paediatric brain tumours: Clinical trial results on a practical barrier to repeat CAR-T dosing in glioma. (CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), CAR-T cell therapy, Glioma & glioblastoma)

Corrections, past 7 days

Confirmed factual corrections to the corpus, with the fixing commit.

2026-09-07 · nhs-galleri: Trial summary said final results were pending; the trial had reported at ASCO 2026 (primary endpoint not met, stage IV incidence down ~14%). (Pipeline-intelligence review while writing the ASCO 2026 digest) · ac8b9f3
2026-09-06 · ezh2, epigenetic-drugs, sarcoma: Described tazemetostat (Tazverik) as approved in epithelioid sarcoma and follicular lymphoma. Ipsen withdrew it from all markets and indications on 9 March 2026 after SYMPHONY-1 showed excess secondary haematologic malignancies. (Companies-expansion review; verified against the FDA alert and Ipsen's press release) · 1d0eb06
2026-09-06 · pubmed-europepmc: TL;DR was a two-word fragment that failed the readability check. (Automated test (tldr length)) · 27e0eb6